-+ 0.00%
-+ 0.00%
-+ 0.00%
DataMeds AI Agrees to Acquire Cancer Blood Test Platform From Todos Medical Estate
Share
Listen to the news
DataMeds AI Agrees to Acquire Cancer Blood Test Platform From Todos Medical Estate
  • DataMeds AI agreed to acquire TBIA cancer blood-testing assets from Todos Medical's estate for its Helomics subsidiary, subject to court approval.
  • Helomics will revalidate the breast and colorectal cancer testing platform to support a laboratory-developed test launch before FDA submissions.
  • The acquisition also includes Todos' license to the LymPro Alzheimer's diagnostic blood test.
  • Issued U.S. and European patents provide exclusivity for the TBIA platform into at least 2034.
  • The TBIA tests lack FDA clearance or approval and are not commercially available in the United States.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending